Osage University Partners has contributed to an oversubscribed series C round for Cyteir, which was led by RA Capital.
Cyteir Therapeutics, a US-based synthetic lethal cancer drug spinout of Jackson Laboratory, completed an $80m series C round yesterday backed by spinout-focused investment firm Osage University Partners (OUP).
RA Capital Management led the oversubscribed round, which additionally featured pharmaceutical firm Novo, Janus Henderson Investors, Acuta Capital Partners, Ally Bridge Group, Avidity Partners, Ample Plus Fund and CaaS Capital Management.
Venrock, Lightstone Ventures, Droia Ventures and an undisclosed US-based healthcare-focused fund filled out the round.
Founded in 2012,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
